



Editor

Tracy Crooks

Reckitt Benckiser Healthcare International Ltd
email: tracy.crooks@reckittbenckiser.com

Advisory Panel

Elliot Brown

Managing Director, Elliot Brown Consulting Ltd

David Cousins

Head of Safe Medication Practice, National Patient Safety Agency

Alison Ewing

Clinical Director of Pharmacy, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Graeme Ladds

Director, PharSafer Associates Ltd.

Sunayana Shah

Scientific & Medical Affairs Manager at the Proprietary Association of Great Britain (PAGB)

Publisher

Joe Ridge

Design & Production

Sarah Beale

Subscriptions

Jill Monk

email: subs@euromedcommunications.com

Published by Euromed Communications Ltd
Passfield Business Centre, Passfield, Liphook,
Hampshire GU30 7SB, UK
Tel: +44 (0)1428 752222
Fax: +44 (0)1428 752223

email: info@euromedcommunications.com
www.euromedcommunications.com

Euromed Communications Ltd also publish
Clinical Research Manual; Paediatric Clinical
Research Manual, Medical Devices Manual and
Compendium of Quality of Life Instruments

Copyright: No part of this journal may be reproduced without written permission from the Publishers. The comments of the contributors are their own and are not necessarily endorsed by the Publisher, Editor or Advisory Panel. Accordingly the Publisher, Editor or Advisory Panel accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement. The Editor's decision is final and no correspondence will be entered into. The utmost care has been taken to ensure accuracy of detail, but the publishers cannot accept responsibility for errors or omissions.

© 2012 Euromed Communications Ltd

ISSN 1752-6752

Contents

November 2012 • Volume 6 Number 4

3 Editorial comment

Tracy Crooks

4 Designing a strategy for kidney toxicity monitoring in clinical trials: pitfalls and solutions

There is a need for new tools to follow kidney function during clinical trials and when designing a surveillance plan. The regulatory agencies are examining different strategies, including renal biomarkers.

Lynda Szczech

11 Proposal on new EU fees for pharmacovigilance: views of the self-care industry

The EU proposal for various fees is challenged by the self-medication industry.

Christell Anquez-Trexler

14 Exon skipping for Duchenne Muscular Dystrophy and the importance of n=1 trials

The author gives an overview of how exon skipping is providing hope for families affected by Duchenne Muscular Dystrophy and how the regulatory framework needs to change quickly with regard to clinical trials and pharmacovigilance if today's generation of sufferers are to benefit.

Nick Catlin

18 Individual safety report causality assessment: perfect, practical or incomplete?

Causality assessment of adverse drug reactions is concluded as being more an art than a science although individual reports can be used to test hypotheses.

Giovanni Furlan, Francesco Tescione and Karolina Szkudlarek